GNTA

Genenta Science S.p.A. (NASDAQ:GNTA) is a clinical-stage biotechnology company founded in 2014 and headquartered in Milan, Italy. The company went public on December 15, 2021, and specializes in developing innovative hematopoietic stem cell gene therapies for treating solid tumors. Genenta focuses on addressing some of the most challenging cancers, particularly brain tumors like glioblastoma multiforme, through its proprietary gene therapy platform that modifies patients' own stem cells to fight cancer.